Innovation is the best medicine

Built on a foundation of deep research, RTW invests with innovative companies looking to bring important new products to patients.

OUR FOCUS ON INNOVATIVE MEDICINE

We have developed expertise through our comprehensive study of industry and academic efforts in targeted areas of significant innovation. By focusing our energies, we believe we can add more value to entrepreneurs and scientists. Our current focus areas include both technology platforms and disease areas.

Technologies

GENE THERAPY

RNA

ANTIBODIES

PROTEINS

DISEASE AREAS

CANCER

RARE DISEASE

NEUROLOGY

CVD

What's New At RTW

RTW Venture Fund spoke to the Association of Investment Companies (AIC) about the impact COVID-19 will have on our industry

With vast swathes of the world in lockdown, the one question on everyone’s minds is how long will it take to develop a vaccine against COVID-19? The Association of Investment Companies (AIC) has spoken to investment company and VCT managers about the prospects for a vaccine and how their portfolio companies are contributing to the fight against coronavirus.

This Disability Rights Activist Wants to Be the First Wheelchair User in Space

There can be irony in even the happiest of sentiments—a fact that is surely not lost on Eddie Ndopu. The son of a South African mother and a Namibian father, Ndopu was born in 1990, the year Namibia attained its independence from South Africa, and just four years before Nelson Mandela became South Africa’s first black President.

RTW Venture Fund Limited lists on the London Stock Exchange

On Wednesday October 30th, the London Stock Exchange welcomed RTW Venture Fund Limited to its first day of trading on the Specialist Fund Segment of the Main Market with a starting NAV and market capitalization of $168M.

Our Successful Partnerships

We support companies through the ups and downs of the often challenging journey to bring therapies to patients.

"Rod dug in our company when many other investors disappeared. He did the work and realized BioCryst’s potential for treating rare diseases such as HAE long before others did."
Jon Stonehouse
Chief Executive Officer
BioCryst Pharmaceuticals
Visit Partner Website

"RTW does deeper diligence than nearly any other investor I know. RTW’s research and guidance in the early days of Rainbow and noninvasive hemoglobin was a valuable resource. They helped us understand the opportunity and have been a trusted partner since."
Joe Kiani
Founder, Chairman & CEO
Masimo
Visit Partner Website

"The RTW Team spotted the argenx investment opportunity ahead of the curve and rapidly developed from an investor to a loyal partner. Their data based approach and desire to understand resonates very well with our company culture."
Tim Van Hauwermeiren
Chief Executive Officer
Argenx
Visit Partner Website

"We view the team at RTW with highest regard. They believed in Alnylam's potential when the rest of the world was skeptical."
John Maraganore, PhD
Chief Executive Officer
Alnylam Pharmaceuticals
Visit Partner Website

"RTW uses scientific and clinical acumen to decipher critical investments. Rod and Piratip were excellent strategic partners who had the foresight to invest in Avexis."
Sukumar Nagendran, MD
Chief Medical Officer
Avexis
Visit Partner Website

"Rod has been with us from the very beginning when we restarted LJPC. His research, insights and support have been critical in making our journey a success."
George F. Tidmarsh, MD, PhD
Chief Executive Officer
La Jolla Pharmaceutical
Visit Partner Website

"RTW is a very insightful and strategic investment firm. They had the foresight to invest in PTC after our acquisition of Emflaza and have spent a significant amount of time and effort to understand the potential of our pipeline."
Stu Peltz
CEO
PTC Therapeutics
Visit Partner Website

"RTW is among the most thoughtful and diligent teams we have encountered. They saw the commercial potential of MACI early on, and have been a tremendous partner to Vericel during a period of rapid growth for the company."
Nick Colangelo
CEO
Vericel
Visit Partner Website

"RTW really took the time to understand our business, and they understood that the reasons that other people had said no were actually the very reasons to say yes. They backed us early and made good on their promise to be a true partner long after Establishment Labs' IPO. They are the entrepreneur's investor and a real value add."
Nick Lewin
Chairman
ESTA
Visit Partner Website

"RTW’s passion for science and rational approach toward therapeutics development have been essential to the RCKT story. Rod and team have an uncanny ability to identify opportunities that no one else has, well ahead of the curve, and the rigorous discipline to water them gently. We value them highly as top shareholders, as founders and integral members of the Board, and most importantly as friends."
Gaurav Shah, MD
CEO & President
Rocket Pharmaceuticals
Visit Partner Website

"The RTW team did deep commercial diligence into the potential for a prophylactic HAE medicine well before other investors. Combined with their deep understanding of science, RTW was a terrific long-term shareholder, as we advanced DX-2930 through the clinic and sought to bring this important therapy to patients."
George Migausky
CFO
Dyax
Visit Partner Website

Our Approach

We believe solving unmet needs is the best way to create value.

Identify unmet needs

We try to ignore the crowd and prioritize where we think unmet needs can be solved by mature science.

Invest in relationships

We believe in developing longterm relationships with great entrepreneurs and scientists who are as passionate about medicine as we are.

Take the long view

We support teams trying to solve the inevitable setbacks that occur when introducing a first in class or disruptive therapy.

The Future Looks Bright

Thanks to the genome, there is more clarity around the causes of disease. Coupled with new exciting modalities that can address genetic diseases in a targeted way, drug innovation is accelerating.

4,000+

Genetic Diseases

Gene sequencing has identified causes for over 4,000 diseases, and is growing at a rate of 200 per year. 

15,000+

Drugs in the Pipeline

The number of new patents has inflected upward. This is translating into both more and higher quality drugs in the pipeline.

500,000+

Lives Saved Each Year

In the coming decade, in the US we expect more than half a million lives a year to be saved across diseases including cancer, neurologic, and rare diseases.